Last edition
News about "Non-Small Cell Lung Cancer "
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Non-small Cell Lung Cancer | 12/05/2026 | By News Bureau
Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27
The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.
Non-small Cell Lung Cancer | 08/05/2026 | By News Bureau | 138
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Non-Small Cell Lung Cancer | 07/05/2026 | By News Bureau
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
Non-small Cell Lung Cancer | 08/04/2026 | By News Bureau | 109
MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer
Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.
Non-small Cell Lung Cancer | 04/04/2026 | By News Bureau | 115
Illumina, Labcorp Expand Partnership to Boost Access to Precision Oncology Testing
Illumina and Labcorp deepen collaboration to expand next-generation sequencing-based cancer testing, improve access to biomarker diagnostics, and accelerate development of precision oncology solutions.
Non-Small Cell Lung Cancer | 19/03/2026 | By News Bureau | 177
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
Non-Small Cell Lung Cancer | 16/03/2026 | By News Bureau | 106
A multi-institutional study published in the Journal for ImmunoTherapy of Cancer finds that an AI-based imaging biomarker can predict immunotherapy outcomes and detect early treatment response in lung cancer patients.
Non-Small Cell Lung Cancer | 11/03/2026 | By News Bureau | 108
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Non-Small Cell Lung Cancer | 11/03/2026 | By News Bureau | 217
Jiahui International Cancer Centre in Shanghai treats a US patient with advanced Non?Small Cell Lung Cancer using Ivonescimab, an experimental immunotherapy currently available only in China.
Non-Small Cell Lung Cancer | 09/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy